RU2490269C2 - ПРОИЗВОДНЫЕ МОРФОЛИНОПУРИНА, ОБЛАДАЮЩИЕ PI3K И/ИЛИ mTOR ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ - Google Patents

ПРОИЗВОДНЫЕ МОРФОЛИНОПУРИНА, ОБЛАДАЮЩИЕ PI3K И/ИЛИ mTOR ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ Download PDF

Info

Publication number
RU2490269C2
RU2490269C2 RU2011119525/04A RU2011119525A RU2490269C2 RU 2490269 C2 RU2490269 C2 RU 2490269C2 RU 2011119525/04 A RU2011119525/04 A RU 2011119525/04A RU 2011119525 A RU2011119525 A RU 2011119525A RU 2490269 C2 RU2490269 C2 RU 2490269C2
Authority
RU
Russia
Prior art keywords
group
mmol
morpholin
contain
purin
Prior art date
Application number
RU2011119525/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2011119525A (ru
Inventor
Кийоси НАКАЯМА
Казуюки СУГИТА
Масаки СЕТОГУТИ
Юити ТОМИНАГА
Масанори САИТОУ
Такаси ОДАГИРИ
Original Assignee
Дайити Санкио Компани, Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дайити Санкио Компани, Лимитед filed Critical Дайити Санкио Компани, Лимитед
Publication of RU2011119525A publication Critical patent/RU2011119525A/ru
Application granted granted Critical
Publication of RU2490269C2 publication Critical patent/RU2490269C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2011119525/04A 2008-10-14 2009-10-13 ПРОИЗВОДНЫЕ МОРФОЛИНОПУРИНА, ОБЛАДАЮЩИЕ PI3K И/ИЛИ mTOR ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ RU2490269C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2008-264797 2008-10-14
JP2008264797 2008-10-14
JP2009121690 2009-05-20
JP2009-121690 2009-05-20
PCT/JP2009/067738 WO2010044401A1 (ja) 2008-10-14 2009-10-13 モルホリノプリン誘導体

Publications (2)

Publication Number Publication Date
RU2011119525A RU2011119525A (ru) 2012-11-27
RU2490269C2 true RU2490269C2 (ru) 2013-08-20

Family

ID=42106564

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011119525/04A RU2490269C2 (ru) 2008-10-14 2009-10-13 ПРОИЗВОДНЫЕ МОРФОЛИНОПУРИНА, ОБЛАДАЮЩИЕ PI3K И/ИЛИ mTOR ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ

Country Status (21)

Country Link
US (2) US8097622B2 (enExample)
EP (1) EP2336132B1 (enExample)
JP (1) JP5090423B2 (enExample)
KR (1) KR101614976B1 (enExample)
CN (1) CN102245607B (enExample)
AU (1) AU2009304789B2 (enExample)
BR (1) BRPI0920199A2 (enExample)
CA (1) CA2740471C (enExample)
CO (1) CO6362009A2 (enExample)
DK (1) DK2336132T3 (enExample)
ES (1) ES2452541T3 (enExample)
IL (1) IL212278A (enExample)
MX (1) MX2011003490A (enExample)
MY (1) MY156456A (enExample)
NZ (1) NZ592761A (enExample)
PL (1) PL2336132T3 (enExample)
PT (1) PT2336132E (enExample)
RU (1) RU2490269C2 (enExample)
TW (1) TWI378933B (enExample)
WO (1) WO2010044401A1 (enExample)
ZA (1) ZA201102449B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2607635C2 (ru) * 2009-11-12 2017-01-10 Ф.Хоффманн-Ля Рош Аг N-9-замещенные пуриновые соединения, композиции и способы применения

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521968A (ja) * 2008-05-30 2011-07-28 ジェネンテック, インコーポレイテッド プリンpi3k阻害剤化合物および使用方法
TWI378933B (en) * 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
CN102260263A (zh) * 2010-05-26 2011-11-30 四川大学 一类二苯胺基嘌呤衍生物及制备方法和医药用途
EP2593455B1 (en) 2010-07-14 2015-03-18 F.Hoffmann-La Roche Ag Purine compounds selective for i3 p110 delta, and methods of use
SG10201510347QA (en) 2010-12-16 2016-01-28 Hoffmann La Roche Tricyclic pi3k inhibitor compounds and methods of use
US9334271B2 (en) 2011-10-28 2016-05-10 Novarits Ag Purine derivatives and their use in the treatment of disease
CN103012284A (zh) * 2012-12-26 2013-04-03 无锡捷化医药科技有限公司 一种2-氨基-5-溴嘧啶类化合物的制备方法
WO2014185368A1 (ja) * 2013-05-13 2014-11-20 第一三共株式会社 5-{8-[(3r)-4-アセチル-3-メチルピペラジン-1-イル]-6-モルホリン-4-イル-9-(2,2,2-トリフルオロエチル)-9h-プリン-2-イル}ピリミジン-2-アミン、およびその薬理上許容される塩の新規な結晶、およびその製造方法
WO2014185367A1 (ja) * 2013-05-13 2014-11-20 第一三共株式会社 モルホリノプリン誘導体の製造方法
US9993460B2 (en) 2013-07-26 2018-06-12 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
KR102369925B1 (ko) * 2013-10-04 2022-03-03 우니베르시태트 바젤 구조적으로 제한된 PI3K 및 mTOR 억제제
MY185268A (en) 2015-03-30 2021-04-30 Daiichi Sankyo Co Ltd Pyrazole derivative useful as pi3k inhibitor
US10765681B2 (en) 2016-02-05 2020-09-08 Academia Sinica Purine compounds possessing anticancer activity
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
US11208442B2 (en) 2016-12-02 2021-12-28 Daiichi Sankyo Company, Limited Endo-beta-N-acetylglucosaminidase
EP3360865A1 (en) 2017-02-13 2018-08-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of cyclopropyldiketopiperazines, and of a key intermediate of ds-5272
TWI837231B (zh) 2018-11-29 2024-04-01 日商第一三共股份有限公司 含有ezh1/2雙重抑制劑之醫藥組合及其用途
CN113368114B (zh) * 2020-03-10 2022-04-22 四川大学 一种吗啉嘧啶类化合物的抗肿瘤应用
JP2024511996A (ja) * 2021-03-17 2024-03-18 タンゴ セラピューティクス, インコーポレイテッド 抗がん剤としてのプリン誘導体

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864145A (en) * 1959-06-02 1961-03-29 Thomae Gmbh Dr K Novel purines and a process for their manufacture
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP3810017B2 (ja) 2000-04-27 2006-08-16 アステラス製薬株式会社 縮合ヘテロアリール誘導体
ATE503743T1 (de) 2000-04-27 2011-04-15 Astellas Pharma Inc Kondensierte heteroarylderivate
WO2002088112A1 (en) 2001-04-27 2002-11-07 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
AU2003284142A1 (en) 2002-10-15 2004-05-04 Synta Pharmaceuticals Corp Aromatic bicyclic heterocyles to modulate 1L-12 production
ES2389253T3 (es) 2002-10-25 2012-10-24 Zenyaku Kogyo Kabushiki Kaisha Compuestos heterocíclicos y agentes antitumorales que comprenden los mismos como ingrediente activo
AU2003294249A1 (en) 2002-11-08 2004-06-03 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
KR101052482B1 (ko) 2002-11-21 2011-07-28 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 포스포티딜이노시톨(pi) 3-키나제 억제제인 2,4,6-삼치환피리미딘 및 암의 치료에서 이들의 사용
AU2005249380C1 (en) * 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
AU2006302148B2 (en) 2005-10-07 2012-12-06 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha
EA016945B1 (ru) 2005-10-07 2012-08-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
GB0525081D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
KR20080083188A (ko) 2006-01-11 2008-09-16 아스트라제네카 아베 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
DK2024372T3 (da) 2006-04-26 2010-09-20 Hoffmann La Roche Thieno[3,2-d]pyrimidin-derivat, der er egnet som P13K inhibitor
KR20090021155A (ko) 2006-04-26 2009-02-27 에프. 호프만-라 로슈 아게 Pi3k 억제제로서의 피리미딘 유도체
CA2650290C (en) 2006-04-26 2015-11-17 Genentech, Inc. Pharmaceutical compounds
EP2046799B1 (en) 2006-04-26 2017-07-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
GB0611152D0 (en) 2006-06-06 2006-07-19 Ucb Sa Therapeutic agents
PL2050749T3 (pl) 2006-08-08 2018-03-30 Chugai Seiyaku Kabushiki Kaisha Pochodna pirymidyny jako inhibitor pi3k i jej zastosowanie
WO2008023161A1 (en) 2006-08-23 2008-02-28 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
WO2008023180A1 (en) 2006-08-24 2008-02-28 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
KR101435231B1 (ko) 2006-08-24 2014-10-02 아스트라제네카 아베 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체
JP2010503651A (ja) 2006-09-14 2010-02-04 アストラゼネカ アクチボラグ 増殖性障害の治療用のPI3K及びmTOR阻害剤としての2−ベンゾイミダゾリル−6−モルホリノ−フェニルピリミジン誘導体
WO2008032089A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032036A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032028A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032091A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032060A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
CN101563340A (zh) 2006-09-14 2009-10-21 阿斯利康(瑞典)有限公司 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物
GB0620818D0 (en) 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
MX337906B (es) 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
TW200831084A (en) 2006-11-21 2008-08-01 Genelabs Tech Inc Anti-viral compounds
US7888352B2 (en) 2006-12-07 2011-02-15 Piramed Limited Phosphoinositide 3-kinase inhibitor compounds and methods of use
ES2571028T3 (es) 2006-12-07 2016-05-23 Genentech Inc Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso
ES2381895T3 (es) 2007-02-06 2012-06-01 Novartis Ag Inhibidores de PI 3-quinasa y métodos para su uso
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
US20080233127A1 (en) * 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
WO2008125833A1 (en) 2007-04-12 2008-10-23 Piramed Limited Pharmaceutical compounds
BRPI0810641A2 (pt) 2007-04-12 2019-09-24 Hoffmann La Roche "compostos farmacêuticos".
GB0707087D0 (en) 2007-04-12 2007-05-23 Piramed Ltd Pharmaceutical compounds
WO2008152387A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Quinazoline derivatives as pi3 kinase inhibitors
WO2008152394A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Pharmaceutical compounds
JP5539190B2 (ja) 2007-06-12 2014-07-02 エフ.ホフマン−ラ ロシュ アーゲー チアゾロピリミジン類及びホスファチジルイノシトール−3キナーゼのインヒビターとしてのそれらの使用
WO2009007748A2 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
EP2205242B1 (en) 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
CN101932587A (zh) 2007-09-24 2010-12-29 吉宁特有限公司 噻唑并嘧啶pi3k抑制剂化合物及使用方法
EP2209786B1 (en) 2007-10-05 2013-02-27 Verastem, Inc. Pyrimidine substituted purine derivatives
US20110009403A1 (en) 2007-10-05 2011-01-13 S*Bio Pte Ltd. 2-morpholinylpurines as inhibitors of pi3k
ES2600919T3 (es) 2007-10-05 2017-02-13 Index Pharmaceuticals Ab Oligonucleótidos para el tratamiento o alivio de edema
KR20100083170A (ko) 2007-10-16 2010-07-21 와이어쓰 엘엘씨 티에노피리미딘 및 피라졸로피리미딘 화합물 및 이의 mTOR 키나제 및 PI3 키나제 억제제로서의 용도
CA2701292C (en) 2007-10-25 2015-03-24 Genentech, Inc. Process for making thienopyrimidine compounds
JP5638955B2 (ja) 2007-10-26 2014-12-10 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Pi3キナーゼ阻害剤として有用なプリン誘導体
GB0721095D0 (en) 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
WO2009066084A1 (en) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
US20090149458A1 (en) 2007-11-27 2009-06-11 Wyeth PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS
GB0723748D0 (en) 2007-12-04 2008-01-16 Ucb Pharma Sa Therapeutic agents
WO2009071895A1 (en) 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
GB0723747D0 (en) 2007-12-04 2008-12-31 Ucb Pharma Sa Therapeutic agents
WO2009071890A1 (en) 2007-12-04 2009-06-11 Ucb Pharma S.A. Tricyclic kinase inhibitors
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
CN102014914A (zh) 2008-01-15 2011-04-13 惠氏有限责任公司 3h-[1,2,3]三唑并[4,5-d]嘧啶化合物、其作为mtor激酶和pi3激酶抑制剂的用途、以及它们的合成
WO2009093981A1 (en) 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
US8557807B2 (en) 2008-01-24 2013-10-15 Signal Rx Pharmaceuticals, Inc. Thienopyranones as kinase inhibitors
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
BRPI0906805A2 (pt) 2008-01-25 2015-07-14 Astrazeneca Ab Composto, processo para preparar o enanciômero puro, composição farmacêutica, uso do enanciômero puro, métodos para prevenir ou tratar doença em um animal de sangue quente, e, combinação
CL2009000241A1 (es) 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
TWI378933B (en) * 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2607635C2 (ru) * 2009-11-12 2017-01-10 Ф.Хоффманн-Ля Рош Аг N-9-замещенные пуриновые соединения, композиции и способы применения

Also Published As

Publication number Publication date
IL212278A0 (en) 2011-06-30
EP2336132B1 (en) 2014-01-01
CA2740471A1 (en) 2010-04-22
US20120071476A1 (en) 2012-03-22
US20100130492A1 (en) 2010-05-27
US8309546B2 (en) 2012-11-13
WO2010044401A1 (ja) 2010-04-22
NZ592761A (en) 2012-05-25
ZA201102449B (en) 2011-12-28
AU2009304789B2 (en) 2012-04-05
US8097622B2 (en) 2012-01-17
KR101614976B1 (ko) 2016-04-22
CO6362009A2 (es) 2012-01-20
CA2740471C (en) 2013-09-17
KR20110067038A (ko) 2011-06-20
HK1158189A1 (en) 2012-07-13
PL2336132T3 (pl) 2014-06-30
CN102245607B (zh) 2014-07-02
JP5090423B2 (ja) 2012-12-05
CN102245607A (zh) 2011-11-16
BRPI0920199A2 (pt) 2019-09-24
MX2011003490A (es) 2011-04-21
EP2336132A1 (en) 2011-06-22
TWI378933B (en) 2012-12-11
PT2336132E (pt) 2014-04-02
EP2336132A4 (en) 2012-03-21
AU2009304789A1 (en) 2010-04-22
IL212278A (en) 2016-07-31
RU2011119525A (ru) 2012-11-27
MY156456A (en) 2016-02-26
JP2011001339A (ja) 2011-01-06
DK2336132T3 (da) 2014-04-07
TW201018690A (en) 2010-05-16
ES2452541T3 (es) 2014-04-01

Similar Documents

Publication Publication Date Title
RU2490269C2 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПУРИНА, ОБЛАДАЮЩИЕ PI3K И/ИЛИ mTOR ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ
ES2539478T3 (es) Inhibidores de PI3K/mTOR cinasa
JP2023103242A (ja) ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
EP4549439A1 (en) Substituted pyrimidine-fused ring inhibitor, method for preparing same, and use thereof
KR20110042153A (ko) 퓨린 pi3k 억제 화합물 및 사용 방법
EP4592296A1 (en) Novel tetraheterocycle compound
EP3733663A1 (en) Quinazoline derivative and use thereof
WO2011041399A2 (en) Pi3k (delta) selective inhibitors
AU2010254161A1 (en) Bicyclic pyrimidine PI3K inhibitor compounds selective for p110 delta, and methods of use
EA026134B1 (ru) Трициклические ингибиторы pi3k и способы их применения
CA2730271A1 (en) Pi3k isoform selective inhibitors
JP2018519304A (ja) ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
WO2011146594A2 (en) Mtor selective kinase inhibitors
EP3546458A1 (en) Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
EP3546463B1 (en) Sulfonamide derivative having coumarin skeleton
JP2011236198A (ja) モルホリノプリン誘導体
CA3161869A1 (en) Heterocyclic compound, and pharmaceutical composition thereof, preparation method therefor, intermediate thereof and application thereof
HK1158189B (en) Morpholinopurine derivative
RU2835105C1 (ru) Содержащая производное с тремя конденсированными кольцами соль или кристаллическая форма и фармацевтическая композиция на их основе
CN118373824A (zh) 取代喹唑啉-4-酮类化合物及其制备方法和用途

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20171014